Dermatology
On demand events
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
On demand materials
Learning objectives
- Reviewing new data about how regulating IL-4 and IL-13 signaling helps normalize skin barrier function in AD
- Identifying how controlling type 2 inflammation early in life via regulation of IL-4 and IL-13 signaling in patients with moderate-to-severe AD may reduce non-atopic comorbidities
- Discussing evidence regarding how early intervention with therapy that regulates IL-4 and IL-13 signaling in infants and children with moderate-to-severe AD may prevent the atopic march
Tags
MAT-GLB-2507267 - 1.0 - 12/2025
